Cardiac resynchronization therapy in mild heart failure: a review of the REVERSE and MADIT-CRT trials.
Cardiac resynchronization therapy has become part of the treatment strategy for advanced, symptomatic heart failure, but newly published trials show that more patients than previously realized may benefit from this therapy, including those with mild heart failure symptoms. The REVERSE and MADIT-CRT trials showed that cardiac resynchronization therapy reduces risk of hospitalization for heart failure and leads to beneficial reverse remodeling of the left ventricle in mild heart failure, especially in patients with prolonged QRS complexes. Ongoing studies aim to expand the indications for this therapy even further, including in patients with normal ejection fractions and a need for frequent ventricular pacing. The current body of evidence favors cardiac resynchronization therapy in patients with a depressed ejection fraction and prolonged QRS, even with minimal or no heart failure symptoms.
Reynolds
Carl R
CR
Division of Cardiology, Medical University of South Carolina, 25 Courtenay Street, ART 7031, Charleston, SC 29425, USA.
Gold
Michael R
MR
D002037:Bundle-Branch Block / Q000628:therapy; D058406:Cardiac Resynchronization Therapy; D017147:Defibrillators, Implantable; D018450:Disease Progression; D006333:Heart Failure / Q000628:therapy*; D006352:Heart Ventricles / Q000294:innervation; D006801:Humans; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome